MARKET

APGE

APGE

Apogee Therapeutics Inc
NASDAQ
78.72
+0.90
+1.16%
After Hours: 79.00 +0.28 +0.36% 17:18 03/30 EDT
OPEN
78.04
PREV CLOSE
77.82
HIGH
79.95
LOW
76.60
VOLUME
988.87K
TURNOVER
--
52 WEEK HIGH
85.04
52 WEEK LOW
26.20
MARKET CAP
5.92B
P/E (TTM)
-18.6739
1D
5D
1M
3M
1Y
5Y
1D
XBI, IBRX, TGTX, APGE: Large Outflows Detected at ETF
NASDAQ · 7h ago
Mizuho Maintains Outperform on Apogee Therapeutics, Raises Price Target to $110
Benzinga · 8h ago
Apogee Therapeutics price target raised to $110 from $105 at Mizuho
TipRanks · 11h ago
APOGEE THERAPEUTICS INC <APGE.O>: MIZUHO RAISES TARGET PRICE TO $110 FROM $105
Reuters · 11h ago
Weekly Report: what happened at APGE last week (0323-0327)?
Weekly Report · 12h ago
U.S. RESEARCH ROUNDUP- Ferguson Enterprises, Hartford Insurance Group, JP Morgan
Reuters · 14h ago
Apogee Therapeutics; CFO Jane Henderson drops 2,000 common shares for $170,000
Reuters · 2d ago
Apogee Therapeutics closes follow-on offering; gross proceeds rise to $403 million
Reuters · 4d ago
More
About APGE
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4Rα. APG279 is for the dual inhibition of OX40L and IL-13.

Webull offers Apogee Therapeutics Inc stock information, including NASDAQ: APGE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APGE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading APGE stock methods without spending real money on the virtual paper trading platform.